BiotechTube

Human Papillomavirus 9-valent Vaccine, Recombinant

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Human Papillomavirus

Conditions

Human Papillomavirus

Trial Timeline

Sep 11, 2017 → May 15, 2019

NCT ID
NCT02968420

About Human Papillomavirus 9-valent Vaccine, Recombinant

Human Papillomavirus 9-valent Vaccine, Recombinant is a approved stage product being developed by Merck for Human Papillomavirus. The current trial status is completed. This product is registered under clinical trial identifier NCT02968420. Target conditions include Human Papillomavirus.

What happened to similar drugs?

13 of 20 similar drugs in Human Papillomavirus were approved

Approved (13) Terminated (4) Active (7)
✅lopinavir/ritonavirAbbVieApproved
✅emtricitabine/tenofovir disoproxil fumarateMerckApproved
✅3-drug anti-HIV therapy + RaltegravirMerckApproved
✅GardasilMerckApproved
✅RaltegravirMerckApproved
✅RaltegravirMerckApproved
✅EBR/GZRMerckApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05625633Phase 2/3Recruiting
NCT02968420ApprovedCompleted

Competing Products

20 competing products in Human Papillomavirus

See all competitors
ProductCompanyStageHype Score
mRNA-1653ModernaPhase 1
0
mRNA-1653ModernaPhase 1
0
mRNA-1345ModernaPhase 1
0
Influenza vaccine, split inactivatedComac MedicalPhase 1
19
CS-8958 + CS-8958 + oseltamivir phosphateDaiichi SankyoPhase 3
40
GSK1265744 30mg + Placebo + GSK1265744 5mgShionogiPhase 2
35
DolutegravirShionogiPhase 3
40
GSK1349572 + efavirenzShionogiPhase 2
35
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
29
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
29
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mgShionogiPhase 1
29
GSK1349572 (dolutegravir) + raltegravirShionogiPhase 3
40
Ortho-Cyclen + Dolutegravir + PlaceboShionogiPhase 1
29
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
29
dolutegravirShionogiPhase 3
40
Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placeboShionogiPhase 3
40
GSK1349572 + EfavirenzShionogiPhase 1
29
GSK1349572ShionogiPhase 1
29
GSK1349572 + PlaceboShionogiPhase 2
35
Dolutegravir + MethadoneShionogiPhase 1
29